Phenoxy-pyrrolidine derivative and its use and compositions
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8524761-B2
Publication Date
2013-09-03
Expiration Date
Abstract
The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.
Core Innovation
The disclosure relates to a phenoxy-pyrrolidine derivative, exemplified by 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone (Formula I), described as acting as a stearoyl-CoA desaturase (SCD1) inhibitor. In mammals, SCD1 is described as being involved in pathways associated with sebum production, and inhibition of SCD1 is linked to reductions in lipid products relevant to dermatologic conditions driven by excess sebum.
The background describes sebum production in mammals and the role of sebaceous glands, and associates excess sebum with dermatologic and cosmetic conditions including acne, oily skin and oily hair, and seborrheic dermatitis. The disclosure states that administration of the compound can treat and/or prevent such conditions by inhibiting SCD1, and includes pharmaceutical compositions and acceptable forms such as salts, solvates, hydrates, and prodrugs.
The disclosure also describes methods of treatment using a therapeutically effective amount of the Formula I compound or pharmaceutically acceptable salt, solvate, or hydrate. Administration routes described include topical administration, oral administration, and parenteral administration, and pharmacological data demonstrate SCD1 inhibition in rat microsomes and a human adipocyte (AdipoRed) assay, together with an in vivo hamster ear model showing reduction of lipid measures including wax ester (WE).
Claims Coverage
The independent claims cover therapeutic administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, in two therapeutic areas. Across the two independent claims, the claims introduce two inventive features, while dependent claims refine the treated subject as human and restrict administration routes to topical, oral, or parenteral.
Formula I SCD1 inhibitor composition for obesity treatment
Administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for treating obesity or reducing body adiposity.
Formula I SCD1 inhibitor composition for atherosclerosis and dyslipidemia treatment
Administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof, for treating atherosclerosis, reducing serum cholesterol, reducing plasma triglycerides, or treating hypertriglyceridemia.
The independent claims are directed to therapeutic administration of a compound of Formula I, or pharmaceutically acceptable salt, solvate, or hydrate, with one claim focused on treating obesity or reducing body adiposity and the other focused on atherosclerosis and dyslipidemic conditions.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treatment and/or prevention of dermatologic and cosmetic conditions driven by excess sebum, including acne, oily skin and oily hair, and seborrheic dermatitis [procedural detail omitted for safety].
Methods for treating obesity or reducing body adiposity by administering a therapeutically effective amount of the Formula I compound or a pharmaceutically acceptable salt, solvate, or hydrate [procedural detail omitted for safety].
Methods for treating atherosclerosis, reducing serum cholesterol, reducing plasma triglycerides, or treating hypertriglyceridemia by administering a therapeutically effective amount of the Formula I compound or a pharmaceutically acceptable salt, solvate, or hydrate [procedural detail omitted for safety].
Interested in licensing this patent?